학술논문
Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease.
Document Type
Article
Author
Source
European Journal of Gastroenterology & Hepatology; Dec2021Supplement, Vol. 34, pe783-e788, 6p
Subject
Language
ISSN
0954691X